The Second Department of General Surgery, Zhuhai People's Hospital, Zhuhai 51900, Guangdong, China.
Department of Hepatobiliary Surgery, The Second Hospital of Longyan, Longyan 364000, Fujian, China.
Aging (Albany NY). 2022 Jul 25;14(14):5908-5924. doi: 10.18632/aging.204193.
Cancer stem cells (CSCs) comprise a small population of cells in cancerous tumors and play a critical role in tumor resistance to chemotherapy. miRNAs have been reported to enhance the sensitivity of pancreatic cancer to chemotherapy. However, the underlying molecular mechanism requires better understanding.
Cell viability and proliferation were examined with CCK8 assays. Quantitative real-time polymerase chain reaction was executed to assess mRNA expression. StarBase database was used to select the target genes of miRNA, which were further affirmed by dual luciferase assay. Transwell assay was used to analyze cell invasion and migration.
We proved that miR-497 could be obviously downregulated in pancreatic cancer tissues and CSCs from Aspc-1 and Bxpc-3 cells. In addition, inhibition of miR-497 evidently accelerated pancreatic CSC gemcitabine resistance, migration and invasion. Moreover, we revealed that nuclear factor kappa B 1 (NFκB1) was prominently upregulated in pancreatic cancer tissues and pancreatic CSCs, and NFκB1 was also identified as a direct target of miR-497. Furthermore, we demonstrated that overexpression of NFκB1 could also notably promote the viability, migration, and invasion of gemcitabine-treated pancreatic CSCs, but this effect could be partially abolished by miR-497 overexpression.
Those findings suggest that miR-497 overexpression could suppress gemcitabine resistance and the metastasis of pancreatic CSCs and non-CSCs by directly targeting NFκB1.
癌症干细胞(CSC)构成了肿瘤中一小部分的细胞,并在肿瘤对化疗的耐药性中发挥关键作用。已经有报道称 miRNA 可增强胰腺癌对化疗的敏感性。然而,其潜在的分子机制仍需要更好地理解。
用 CCK8 法检测细胞活力和增殖。通过定量实时聚合酶链反应(qRT-PCR)评估 mRNA 表达。StarBase 数据库用于选择 miRNA 的靶基因,并用双荧光素酶报告基因实验进一步验证。Transwell 小室实验用于分析细胞侵袭和迁移。
我们证明 miR-497 在胰腺癌组织和 Aspc-1 及 Bxpc-3 细胞来源的 CSCs 中明显下调。此外,抑制 miR-497 明显加速了胰腺 CSC 对吉西他滨的耐药性、迁移和侵袭。此外,我们揭示了核因子 κB1(NFκB1)在胰腺癌组织和胰腺 CSCs 中明显上调,并且 NFκB1 也被鉴定为 miR-497 的直接靶基因。此外,我们证明过表达 NFκB1 也可显著促进吉西他滨处理的胰腺 CSCs 的活力、迁移和侵袭,但这种作用可被 miR-497 的过表达部分消除。
这些发现表明,miR-497 的过表达可通过直接靶向 NFκB1 来抑制胰腺 CSCs 和非 CSCs 的吉西他滨耐药性和转移。